Gemoscan Canada Announces Appointment of Vice President, Investor Relations

Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") - (TSX VENTURE:GES)
(MUN:1GE) is pleased to announce the appointment of Ann Hawley as Vice
President, Investor Relations, effective immediately. Ms. Hawley will report to
President and CEO, Brian Kalish. 


Ms. Hawley brings more than 20 years of experience in the investor relations
field, across multiple markets and industries, to the Gemoscan team. Prior to
joining Gemoscan, she was Vice President Investor Relations at Colossus Minerals
Inc., an emerging gold producer. Previously she was Director Investor Relations
and Corporate Communications at Ivernia Inc., a base metals mining, exploration
and development company. Prior to Ivernia, she was Director, Investor Relations
at Intrepid Mines Limited, and held senior investor relations positions in
several technology and network communications companies based in Silicon Valley,
California. Ms. Hawley will be the primary interface between Gemoscan and the
investment community and she will oversee the development and implementation of
an overall corporate communications plan focused on building relationships with
the broker and institutional investment communities while also driving general
market awareness and communications strategies at Gemoscan.


As part of the compensation package, which includes an annualized salary,
Gemoscan will issue Ms. Hawley 300,000 incentive stock options to be granted
pursuant to the Company's stock option plan (the "Option Plan") and the rules of
the TSX Venture Exchange. The options are exercisable at $0.37 for five years in
accordance with the Option Plan and will vest in four equal installments every
three months commencing on the grant date.


ABOUT GEMOSCAN CANADA, INC.

Founded in 2003, Gemoscan Canada Inc. owns and markets the HEMOCODE(TM) Food
Intolerance System, a personalized naturopathic nutritional program that
promotes well-being. HEMOCODE(TM) uses patented technology and services to
provide consultation and recommendations to simplify the management of food
sensitivities. Gemoscan Canada, Inc. trades its shares on the Toronto Venture
Exchange (TSX-V) under the symbol GES.


Forward-Looking Information

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available to
Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward-looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.

Gemoscan Canada, Inc. (TSXV:GES)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024